PolycapTM is a capsule or pill developed by Cadila Pharmaceuticals Ltd. India. The pill is a combination of Atenolol (50 mg), Thiazide (12·5 mg), Ramipril (5 mg), Simvastatin (20 mg) and Aspirin (100 mg) for primary prevention of cardiovascular events and stroke.
According to Cadila Pharmaceuticals commissioned and sponsored ‘The Indian Polycap Study’ PolycapTM brings down the risk of coronary heart disease by 62% and stroke by 48%. PolycapTM can reduce multiple risk factors for cardiovascular diseases such as lowering the blood pressure, the heart rate, the lipids and decreasing the stickiness of the platelets. ‘The polypill - can reduce cardiovascular events by more than 80% in healthy individuals.’ This was the conclusion of the study of the effect of the Polycap on blood pressure, lipids, heart rate, and urinary thromboxane B2, and of the assessment of its tolerability.
"The thought that people might be able to take a single pill to reduce multiple cardiovascular risk factors has generated a lot of excitement, it would certainly revolutionize heart disease prevention as we know it."
"Number one, it will reduce the cost of the pills. And it will improve compliance. We know that more people are apt to take one pill compared to five or six pills."
By one week the refereed British medical journal ‘The Lancet’ revealed the TIPS on Cadila Pharmaceuticals’ development.
Within fifteen days of online publication, the TIPS article emerged as one of the five most read articles for month of March in 2009. (TheLancet.com - Home Page)
Polycap is the first global Indian product featuring at ‘The Lancet’
The Lancet is the world's leading independent general medical journal. The journal's coverage is international in focus and extends to all aspects of human health.
The Lancet is published weekly from editorial offices in London and New York. It aims to publish original primary research papers, and review articles of high standard. The Lancet is edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Drawing on an international network of advisers and contributors, The Lancet meets the needs of physicians by adding to their clinical knowledge and alerting them to current issues affecting the practice of medicine worldwide. The blend of challenging editorials, signed commentaries, original research, commissioned reviews, an international news section, and the views of readers in the letters pages make The Lancet an essential weekly read for physicians all over the world.
The Lancet is published weekly by Elsevier, part of Reed Elsevier. One of the world's best-known and most respected general medical journals, The Lancet was founded in 1823 by Thomas Wakley, who named it after the surgical instrument called a lancet, as well as an arched window ("to let in light"). As of 2008, the editor-in-chief is Richard Horton. The Lancet has taken a stand on several important medical issues. Recent examples include criticism of the World Health Organization, rejecting the efficacy of homeopathy as a therapeutic option, disapproval during the time Reed Exhibitions hosted arms industry fairs, and a call in 2003 for tobacco to be made illegal.
The Lancet has a significant readership throughout the world with a high impact factor, especially via its website The Lancet.com, which has attracted over 1.8 million registered users since its launch in 1996. It publishes original research articles, review articles, editorials, book reviews, correspondences, amidst other regulars such as news features and case reports. The Lancet is considered to be one of the "core" general medical journals.
To explore more visit www.thelancet.com